To assess and improve the quality of antibiotic use in patients with community-acquired pneumonia (CAP) and acute exacerbation of chronic bronchitis or chronic obstructive pulmonary disease (AECB), a valid set of quality indicators is required. This set should also be applicable in practice.
the management of CAP, but the results have often varied in terms of their relevance, scientific soundness, and interpretability [10] . To our knowledge, no quality indicators have been suggested for antibiotic use in hospitalized patients with AECB. Where possible, indicators should be based directly on scientific evidence. However, like in many fields of medicine, there is only a limited scientific basis for recommendations regarding antibiotic use in cases of LRTI [10] . To develop valid quality indicators, it is necessary to use a systematic procedure that combines available evidence and expert opinion to assess additional aspects of care for which evidence alone is insufficient, absent, or methodologically weak [11, 12] .
Development of valid quality indicators is, however, not enough. Validity in itself does not guarantee applicability in a specific setting. To assess applicability, again, a rigorous approach is required: indicators should be tested on important clinimetric characteristics, such as feasibility, reliability, opportunity for improvement, and case-mix stability [13] .
In this article, we describe how we systematically developed a valid set of quality indicators for antibiotic use in hospitalized patients with LRTI. In addition, we describe a method to assess their applicability in daily practice. We used our quality-improvement project for antibiotic use in LRTI in 8 Dutch hospitals as a test case.
METHODS
A set of indicators was developed in 4 steps. Applicability was tested in 5 steps. Figure 1 shows a flowchart detailing the steps involved in developing the indicators and testing their applicability.
Development of a Valid Set of Indicators
Preselection of potential indicators. Four independent investigators (J.S., M.H., and 2 guideline experts) preselected key recommendations from national guidelines [6, 7] . Quality indicators that were published in international guidelines for CAP [2] [3] [4] [5] or in the literature [10, [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] were added to the list of potential indicators (table 1 and table A1 in the Appendix). For the latter purpose, a literature search was performed (table  2) .
Evidence-based assessment of the indicators. Every potential indicator was investigated to determine the degree of scientific evidence that linked indicator performance to outcome (i.e., mortality, morbidity, length of hospitalization, and costeffectiveness). We started by reviewing whether the source (guideline or literature) of the potential indicator specified any references. A search of the PubMed database was then performed using search terms specific to the quality indicator topic. On the basis of the available literature, all of the potential indicators were given 1 of 4 grades (A-D) of supporting evidence (table A2 in the Appendix). Potential indicators with contradictory evidence were excluded, and grade A recommendations were immediately accepted as valid (i.e., evidencebased) indicators. The remaining indicators (grades B, C, or D) were tested further in an expert consensus procedure.
Rating and adding procedure by an expert panel. A panel of 11 opinion leaders in medical microbiology, infectious diseases, respiratory medicine, and quality-of-care medicine were asked to conduct a consensus procedure for the preselected set of indicators [11, 34] . In the 2-round consensus procedure, the panel judged the potential indicators on the basis of 3 criteria: (1) clinical relevance to the patient health benefit, (2) relevance to reducing antimicrobial resistance, and (3) relevance to costeffectiveness. A 5-category Likert scale was used that varied from "completely disagree" (category 1) to "completely agree" (category 5) . An extra answer category could be marked if the expert could not decide about a particular question. A definition of these constructs was provided in the covering letter. In the second round, the expert panel had the opportunity to comment on the proposed indicators and to add or modify potential indicators for evaluation.
Only indicators with 170% agreement between the experts on 1 criterion were selected in the first round. Indicators with 170% disagreement on all 3 criteria were rejected [34] . All of the other indicators, including those added or modified by the experts, were reevaluated in the second round.
Final set of indicators. The final step in devising the set of indicators consisted of operationalizing them by defining numerators and denominators. An algorithm for every indicator revealed how it had been deduced from the available data.
Assessment of Applicability of Quality Indicators in a Specific Patient Sample
Setting and study population. To test applicability in a specific setting, feasibility of data collection, reliability, opportunity for improvement, and case-mix stability were determined in a demonstration data set (Dutch LRTI quality-improvement project). A prospective observational audit was performed at 8 medium-sized hospitals, including both teaching and nonteaching facilities, in the southeastern part of The Netherlands. Patients with CAP and AECB were selected on the basis of formal inclusion criteria.
Data collection. During a 6-month period, trained research assistants made twice-weekly reviews of the charts of all of the patients admitted to internal medicine and respiratory medicine hospital wards. All of the relevant patients were followed-up during their period of hospitalization and until 30 days after discharge from the hospital. Data were collected from admission sheets, medical and nursing records, medication charts, and microbiological and radiological testing reports. After recording data on the preprinted standardized data forms, 2 assistants entered the results into a database. Applicability steps and analysis. Clinimetric characteristics of quality indicators-including feasibility, reliability, opportunity for improvement, and case-mix stability-were defined and determined in the demonstration data set. In addition, factor analysis was performed for data (i.e., indicator) reduction purposes.
Feasibility. Feasibility of data abstraction was defined as the percentage of missing values per indicator (i.e., the percentage of indicator values that could not be calculated because у1 element of the algorithm could not be retrieved from the available records). Feasibility was considered poor if this percentage exceeded 25%.
Reliability. To assess the reliability of our data collection, the percentage of agreement between 2 data reviewers on the level of indicator outcome, corrected for chance, was expressed in k coefficients. A sample consisting of 10% of the records of 2 hospitals was collected by 2 independent data reviewers. Scores of were considered to be moderate, 0.41 р k р 0.6 were considered to be good, and were 0.61 р k р 0.8 k 1 0.8 considered to be very good [35] . Values of !0.4 were considered to be poor and led to elimination of the indicator.
Potential opportunity for quality improvement. Quality measures must be capable of detecting changes in the quality of care to discriminate between and within subjects. If indicator performance is invariably high, with little variation, this renders an indicator less sensitive and thus less successful as an indicator. From the viewpoint of internal quality improvement, indicators with a performance score 185% were defined as having limited room for improvement. Indicators with a performance score 185% in all participating hospitals were not selected [8, 36] .
Case-mix stability. Case-mix stability is an important in- Table 2 . Summary of a systematic literature search for quality indicators for antibiotic use in the treatment of community-acquired pneumonia (CAP) and acute exacerbation of chronic bronchitis or chronic obstructive pulmonary disease (COPD).
Methods
Medical subject heading terms used were"quality of care," "quality," "performance," "recommended processes of care," "indicators," "antibiotic use," "antibiotics" combined with "community-acquired pneumonia," "pneumonia," and "CAP" or combined with "exacerbation," "exacerbation COPD," and "exacerbation of chronic bronchitis."
Original peer-reviewed articles were selected between January 1990 and July 2004 from the PubMed database.
Proposed indicators could cover the entire process of care from admission to discharge, but had to relate in some way to antibiotic use. Diagnostic procedures were included as long as they were likely to influence the use of antibiotics (i.e., choice of drug, dosage, or duration of therapy). Excluded articles included all articles with children as study subjects, articles that did not specifically address CAP or exacerbation of COPD, articles that did not address antibiotic use, articles that were letters or case reports, articles that addressed patients with HIV/AIDS, and articles that only addressed patient outcome indicators (e.g., mortality and length of hospitalization). Results
The initial search yielded 177 articles involving CAP; 156 of these studies were excluded on the basis of titles and abstracts. Reasons for exclusion were as follows: article did not specifically address CAP (77 articles); article did not address indicators or only addressed outcome indicators for CAP (59); article addressed patients with HIV/AIDS (7); article had children as study subjects (6); and article was letter or case report (7) . The remaining 21 articles [10, [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] were reviewed for indicators. From these studies, 4 additional potential indicators (i.e., indicators that had not already been derived from national guidelines) were added to the list. These included initiation of antibiotic use !4 h after presentation, prescription of antibiotic therapy in adherence with national guidelines, performance of blood and sputum cultures !24 h after presentation, and performance of blood and sputum cultures before empirical therapy. No relevant articles were found for acute exacerbation of chronic bronchitis or COPD that provided indicators for antibiotic use.
dicator asset, enabling application of an indicator to monitor quality in a specific hospital over time and to compare hospitals of different sizes and settings [13] . The relationship between certain patient characteristics and the indicator result was analyzed to decide whether correction for case mix was necessary.
In the CAP indicators, we studied the distribution of outcome according to age (either у70 years or !70 years), sex, and Pneumonia Severity Index [37] (either рIII or 1III). For AECB, no validated severity-of-illness score was available, so we used the most recent forced expiratory volume in 1 second (FEV 1 ) value (expressed as a percentage of the predicted value) as a substitute. The need for case-mix correction did not lead to exclusion from our final set.
Factor analysis. Factor analysis was performed to detect relationships between indicators, thus potentially leading to a reduction in the number of indicators [36] . To perform data reduction through factor analysis, a minimum of correlation between the items is required. We used Bartlett's sphericity test (in which P should be !.05), Kaiser-Maier-Olkin measure of sampling adequacy (MSA) (in which MSA should be 10.5), and R 2 (in which R 2 should be 10.20) . This procedure was performed separately for the sets of CAP and AECB indicators.
RESULTS

Development of a valid set of indicators.
In the first step, 10 potential indicators for CAP and 5 for AECB were preselected from national and international guidelines and the literature ( figure 1 and table 2) . No "good supporting evidence" (grade A) could be found that linked process to outcome in any of these indicators. None of the indicators had to be excluded because of contradictory evidence (table 1) .
All 15 potential indicators were entered into the iterated consensus procedure. In the first round, 4 recommendations were immediately selected for both CAP and AECB. No indicators were eliminated. Six new items (4 for CAP and 2 for AECB) were added by the expert panel. One potential indicator was revised, and another was split into 2 separate indicators. In the second round, 8 potential indicators (5 for CAP and 3 for AECB) out of 14 (11 for CAP and 3 for AECB) remaining recommendations were selected. The ultimate set was considered to be valid. It consisted of 12 indicators for CAP and 7 indicators for AECB.
Assessment of applicability of quality indicators in a specific patient sample. All 19 validated indicators were tested using a sample of 443 hospitalized patients with CAP and 456 hospitalized patients with AECB (tables 3 and 4). A review was made of the distribution of performance of the indicators over the 8 hospitals. Although there was wide variability in outcome (table 3) , this was not because of the patient mix (data not shown).
Feasibility. Feasibility of 3 indicators was poor in our demonstration data set of Dutch patients with LRTI. Performing cultures of blood and sputum samples before the first antibiotic dose was administered showed poor feasibility: 55% of the subjects had missing values for timely culturing of blood samples, and 75% had missing values for timely culturing of sputum samples. These 2 indicators were rejected. It proved to be impossible to construct an algorithm for 1 of the 12 indicators for CAP ("change antibiotic therapy if no clinical improvement within 72 h of initiation"). We were unable to operationalize "no clinical improvement." This indicator was considered to be nonfeasible (100% of the subjects had missing values) and was also rejected.
Reliability. One indicator (timeliness of antibiotic admin- istration) received a score of , indicating moderate in-k p 0.5 terobserver reliability. All other indicators showed k scores of 10.6 (i.e., good or very good). No indicator was rejected.
Opportunity for improvement. The AECB recommendation to not prescribe macrolides as a first-choice antibiotic showed a high outcome (performed in 190% of cases) in each participating hospital, and thus it showed little room for improvement. This indicator was rejected for use as a quality indicator in our quality-improvement project. For the AECB indicator "adapt dose and dose interval to renal function," there was a high median performance rate (96%), but an outlier hospital with a performance rate of 73% of cases was detected, and the indicator was, therefore, not rejected.
Need for case-mix correction. Two CAP indicators needed correction for age: "adapting dose and dose interval of antibiotics to renal function" ( ) and "obtaining samples P p .0001 for blood cultures" ( ). Regarding sex, sputum samples P p .003 were obtained significantly more often from men than from women ( ). All of the other CAP indicators showed P p .001 stable patterns of distribution over the 3 patient characteristics (age, sex, and severity of illness). In the population of patients with AECB, sputum cultures were performed more consistently in patients with an FEV 1 value of р60% ( ). The need P p .033 for case-mix correction did not lead to exclusion from our set but should be taken into account for interpretation of performance scores in our group of hospitals.
Factor analysis. For CAP and AECB, Bartlett's sphericity test ( and ), Kaiser-Maier-Olkin MSA (0.463 P p .091 P p .161 and 0.489), and R 2 (0.147 and 0.137) indicated that no relevant correlation was detected between the indicators. Subsequently, further factor analysis, performed in an attempt to reduce the number of indicators, was not considered useful. Our set comprises intrinsically strong indicators.
DISCUSSION
On the basis of a carefully planned procedure that combined evidence and expert opinion, we developed a set of valid quality indicators for antibiotic use in hospitalized patients with LRTIs. In addition, we showed the importance of subjecting these indicators to a practice test before using them to measure and improve the quality of care in a specific setting. In our example, only a part of the valid set (15 of 19 indicators) turned out to be applicable in daily practice.
None of our potential indicators could rely on a firm body of evidence that linked process to outcome of care. "Timely administration of antibiotics" and "prescription of an empirical antibiotic regimen according to current guidelines" were consistently associated with improved survival in patients with CAP, but this was only in observational, retrospective studies [38, 39] . Several prospective interventional trials have demonstrated that early-switch strategies are cost-effective and safe, but no randomized, controlled trials have yet confirmed these results [40, 41] . No firm associations were found between outcome and most of the other suggested indicators. Results from our expert consensus procedure demonstrated that these nonevidence-based recommendations may still be regarded as valuable by professionals. Changing from broad-spectrum to narrow-spectrum therapy once culture results become available will probably not directly affect short-term outcome for the individual patient. However, it has a theoretical effect on reducing the development of resistance, and it may thus turn out to be crucial for the outcome of future patients [42] . Unfortunately, studies that link process indicators with resistance patterns are confronted with large methodological difficulties, so it will be difficult to prove any definite relationship. Using a technique that systematically combined evidence and consensus enabled us to assess (and thus improve) a broader range of aspects than would have been possible if quality indicators had been restricted to evidence only. Even if our set of indicators is considered to be valid, its applicability in daily practice has several other important prerequisites. In our demonstration data set of hospitalized Dutch patients with LRTI, most of the indicators showed reasonable applicability (i.e., they were found to be feasible and reliable and showed room for improvement). Unfortunately, the feasibility of data collection turned out to be poor for some indicators. These findings support our belief that Dutch hospitals do not have systematic and robust registration systems (e.g., for registering the timing of hospital procedures). This currently constitutes a major barrier against the application of these kinds of quality indicators in The Netherlands, not only for research purposes, but also for monitoring the quality of daily practice. Once Dutch hospitals are required to collect these data-for example, as part of their normal review process-documentation will probably pick up. Timing of procedures caused major feasibility problems in our example, but in other countries, the feasibility of these indicators may be very different. US hospitals, for example, readily collect data for antibiotic timing as part of their normal review and accreditation process. In the United States, however, other data collection problems may arise, jeopardizing feasibility. This underlines the importance of performing an applicability test before using indicators to measure and improve the quality of care in a specific setting.
In our applicability test, we used a performance rate of 85% of cases (for each participating hospital) as a cut-off value to exclude indicators. From the viewpoint of internal quality improvement, indicators that score 185% in all hospitals have little room for improvement. Quality measures must be capable of detecting changes to discriminate between and within subjects. If indicator performance is invariably high with little interhospital variation, this renders an indicator less sensitive and thus less successful as an indicator [36] . The main goal of subjecting our set of indicators to this criterion was to prioritize the indicators most in need of improvement in a quality-improvement project (i.e., those indicators with low performance rates and/or large interhospital variation). Using "opportunity for quality improvement" as a selection criterion is particularly important for internal quality-improvement efforts. If, on the other hand, the indicator set is to be used for accreditation purposes, for example, room for improvement might not be desirable as a selection criterion; the trend in regulating and accrediting organizations is to provide indicator sets that highlight excellent performance, as well as merely meet minimal standards [13] .
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Earlier sets of indicators, developed using somewhat different methodology, show many similarities to our set [10, 24, 43] . In some of these studies, clinimetric criteria, such as feasibility, reliability, and opportunity for improvement, were appraised by the clinical judgement of experts [10] and not on the basis of empirical data from real practice. However, in our experience, the feasibility of data collection is often overrated by professionals. All members of our expert panel believed that it was feasible to measure the time lag between performance of blood cultures and first antibiotic administration, but in reality, this could be done for only 25% of patients.
In summary, we developed a robust set of intrinsically strong indicators using rigorous methodology that combined the available evidence and expert opinion. Performance assessment in a practical test showed that some indicators were flawed by poor feasibility of data collection. Our experience demonstrates that, before implementation of a theoretically sound set of indicators, a practice test should be performed to assess its applicability in daily practice. 
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